Reading the tape
NASDAQ: CGTX
Cognition Therapeutics, Inc.
Healthcare · Biotechnology
Market Cap
$94.19M
52w High
$3.83
52w Low
$0.22
P/E
-4.85
Volume
826.54K
Outstanding Shares
73.58M
Price vs Fundamentals
Why The Stock Is Moving
Fundamentals are supporting the moveModerate confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: 194.39%FCF (TTM): 13.66%
What changed
The stock rose 194.39% over the last year. Free cash flow grew 13.66% over the trailing twelve months.
What the market seems to be pricing
The stock move broadly lines up with stronger business momentum. The operating data is doing enough work that the move does not need an overvaluation story to explain it.
What would invalidate this read
If revenue growth, margins, or free cash flow roll over while the stock keeps climbing, more of the move would be coming from multiple expansion than business progress.
Company profile
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina.
CEOLisa Ricciardi
SectorHealthcare
IndustryBiotechnology
Employees25
IPO dateOct 8, 2021
Valuation
Forward P/E—
EV/EBITDA-1.30
Enterprise value$62.06M
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth—
Gross margin0%
Operating margin0%
ROE-68.53%▲62.17%vs FY2024
Analyst consensus
RatingBuy
Target price—
6
Buy
1
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 6, 2026
Q2 FY26 · EPS est -$0.06 · Revenue est $4.4M
View